FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996472975> ?p ?o ?g. }

• W1996472975 endingPage "1563" @default.
• W1996472975 startingPage "1552" @default.
• W1996472975 abstract "To evaluate the efficacy, pharmacokinetics, immunogenicity, and safety of multiple infusions of a chimeric monoclonal anti-tumor necrosis factor alpha antibody (cA2) (infliximab; Remicade, Centocor, Malvern, PA) given alone or in combination with low-dose methotrexate (MTX) in rheumatoid arthritis (RA) patients.In a 26-week, double-blind, placebo-controlled, multicenter trial, 101 patients with active RA exhibiting an incomplete response or flare of disease activity while receiving low-dose MTX were randomized to 1 of 7 groups of 14-15 patients each. The patients received either intravenous cA2 at 1, 3, or 10 mg/kg, with or without MTX 7.5 mg/week, or intravenous placebo plus MTX 7.5 mg/week at weeks 0, 2, 6, 10, and 14 and were followed up through week 26.Approximately 60% of patients receiving cA2 at 3 or 10 mg/kg with or without MTX achieved the 20% Paulus criteria for response to treatment, for a median duration of 10.4 to >18.1 weeks (P < 0.001 versus placebo). Patients receiving cA2 at 1 mg/kg without MTX became unresponsive to repeated infusions of cA2 (median duration 2.6 weeks; P=0.126 versus placebo). However, coadministration of cA2 at 1 mg/kg with MTX appeared to be synergistic, prolonging the duration of the 20% response in >60% of patients to a median of 16.5 weeks (P < 0.001 versus placebo; P=0.006 versus no MTX) and the 50% response to 12.2 weeks (P < 0.001 versus placebo; P=0.002 versus no MTX). Patients receiving placebo infusions plus suboptimal low-dose MTX continued to have active disease, with a Paulus response lasting a median of 0 weeks. A 70-90% reduction in the swollen joint count, tender joint count, and C-reactive protein level was maintained for the entire 26 weeks in patients receiving 10 mg/kg of cA2 with MTX. In general, treatment was well tolerated and stable blood levels of cA2 were achieved in all groups, except for the group receiving 1 mg/kg of cA2 alone, at which dosage antibodies to cA2 were observed in approximately 50% of the patients.Multiple infusions of cA2 were effective and well tolerated, with the best results occurring at 3 and 10 mg/kg either alone or in combination with MTX in approximately 60% of patients with active RA despite therapy with low-dose MTX. When cA2 at 1 mg/kg was given with low-dose MTX, synergy was observed. The results of the trial provide a strategy for further evaluation of the efficacy and safety of longer-term treatment with cA2." @default.
• W1996472975 created "2016-06-24" @default.
• W1996472975 creator A5008046164 @default.
• W1996472975 creator A5014323914 @default.
• W1996472975 creator A5015843104 @default.
• W1996472975 creator A5016157822 @default.
• W1996472975 creator A5025407380 @default.
• W1996472975 creator A5049447415 @default.
• W1996472975 creator A5052424289 @default.
• W1996472975 creator A5057580992 @default.
• W1996472975 creator A5063329660 @default.
• W1996472975 creator A5076685429 @default.
• W1996472975 creator A5078467243 @default.
• W1996472975 creator A5090753435 @default.
• W1996472975 date "1998-09-01" @default.
• W1996472975 modified "2023-10-10" @default.
• W1996472975 title "Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis" @default.
• W1996472975 cites W1963627373 @default.
• W1996472975 cites W1971685694 @default.
• W1996472975 cites W1972617333 @default.
• W1996472975 cites W1973123086 @default.
• W1996472975 cites W1975228750 @default.
• W1996472975 cites W1983145703 @default.
• W1996472975 cites W1991393467 @default.
• W1996472975 cites W1997376627 @default.
• W1996472975 cites W2020250668 @default.
• W1996472975 cites W2026342001 @default.
• W1996472975 cites W2031670584 @default.
• W1996472975 cites W2040505385 @default.
• W1996472975 cites W2043287930 @default.
• W1996472975 cites W2048462515 @default.
• W1996472975 cites W2059459516 @default.
• W1996472975 cites W2088158803 @default.
• W1996472975 cites W2091830592 @default.
• W1996472975 cites W2101840353 @default.
• W1996472975 cites W2142273705 @default.
• W1996472975 cites W2143939606 @default.
• W1996472975 cites W2149899765 @default.
• W1996472975 cites W2152348310 @default.
• W1996472975 cites W2159106700 @default.
• W1996472975 cites W2161827425 @default.
• W1996472975 cites W2162716725 @default.
• W1996472975 cites W2172011800 @default.
• W1996472975 cites W2176899369 @default.
• W1996472975 cites W2328587823 @default.
• W1996472975 doi "https://doi.org/10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w" @default.
• W1996472975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9751087" @default.
• W1996472975 hasPublicationYear "1998" @default.
• W1996472975 type Work @default.
• W1996472975 sameAs 1996472975 @default.
• W1996472975 citedByCount "1553" @default.
• W1996472975 countsByYear W19964729752012 @default.
• W1996472975 countsByYear W19964729752013 @default.
• W1996472975 countsByYear W19964729752014 @default.
• W1996472975 countsByYear W19964729752015 @default.
• W1996472975 countsByYear W19964729752016 @default.
• W1996472975 countsByYear W19964729752017 @default.
• W1996472975 countsByYear W19964729752018 @default.
• W1996472975 countsByYear W19964729752019 @default.
• W1996472975 countsByYear W19964729752020 @default.
• W1996472975 countsByYear W19964729752021 @default.
• W1996472975 countsByYear W19964729752022 @default.
• W1996472975 countsByYear W19964729752023 @default.
• W1996472975 crossrefType "journal-article" @default.
• W1996472975 hasAuthorship W1996472975A5008046164 @default.
• W1996472975 hasAuthorship W1996472975A5014323914 @default.
• W1996472975 hasAuthorship W1996472975A5015843104 @default.
• W1996472975 hasAuthorship W1996472975A5016157822 @default.
• W1996472975 hasAuthorship W1996472975A5025407380 @default.
• W1996472975 hasAuthorship W1996472975A5049447415 @default.
• W1996472975 hasAuthorship W1996472975A5052424289 @default.
• W1996472975 hasAuthorship W1996472975A5057580992 @default.
• W1996472975 hasAuthorship W1996472975A5063329660 @default.
• W1996472975 hasAuthorship W1996472975A5076685429 @default.
• W1996472975 hasAuthorship W1996472975A5078467243 @default.
• W1996472975 hasAuthorship W1996472975A5090753435 @default.
• W1996472975 hasBestOaLocation W19964729751 @default.
• W1996472975 hasConcept C112705442 @default.
• W1996472975 hasConcept C126322002 @default.
• W1996472975 hasConcept C141071460 @default.
• W1996472975 hasConcept C142724271 @default.
• W1996472975 hasConcept C17991360 @default.
• W1996472975 hasConcept C204787440 @default.
• W1996472975 hasConcept C27081682 @default.
• W1996472975 hasConcept C2776694085 @default.
• W1996472975 hasConcept C2777077863 @default.
• W1996472975 hasConcept C2777138892 @default.
• W1996472975 hasConcept C2777575956 @default.
• W1996472975 hasConcept C2781059491 @default.
• W1996472975 hasConcept C71924100 @default.
• W1996472975 hasConcept C90924648 @default.
• W1996472975 hasConceptScore W1996472975C112705442 @default.
• W1996472975 hasConceptScore W1996472975C126322002 @default.
• W1996472975 hasConceptScore W1996472975C141071460 @default.
• W1996472975 hasConceptScore W1996472975C142724271 @default.
• W1996472975 hasConceptScore W1996472975C17991360 @default.
• W1996472975 hasConceptScore W1996472975C204787440 @default.
• W1996472975 hasConceptScore W1996472975C27081682 @default.

• next